Hematopoietic Stem-Cell Transplantation for Acute Myelogenous Leukemia

Hematopoietic stem cell transplantation (HSCT) is a key therapeutic modality for the management of acute myeloid leukemia (AML). Advances in preparative regimens and post-transplant supportive care have extended the use of HSCT to populations that were excluded in the past, such as the elderly and those with comorbidities. However, with increasing eligibility come the difficulties of integrating transplantation with new medications with efficacy in AML. Herein, we discuss HSCT, including the types of transplants offered for patients with AML, preparative regimens, timing of transplant, and factors involved in patient selection. We also speculate on future advances and directions that may alter the way HSCT is currently performed to treat AML.